314 related articles for article (PubMed ID: 10680736)
1. Newcastle disease virus (NDV): brief history of its oncolytic strains.
Sinkovics JG; Horvath JC
J Clin Virol; 2000 Feb; 16(1):1-15. PubMed ID: 10680736
[TBL] [Abstract][Full Text] [Related]
2. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
3. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
4. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
5. Newcastle disease virus as an oncolytic agent.
Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
Zamarin D; Palese P
Future Microbiol; 2012 Mar; 7(3):347-67. PubMed ID: 22393889
[TBL] [Abstract][Full Text] [Related]
8. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
9. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
10. [Progress in using Newcastle disease virus for tumor therapy: a review].
Wu Y; Hao J; Li D
Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
[TBL] [Abstract][Full Text] [Related]
11. Optimizing environmental safety and cell-killing potential of oncolytic Newcastle Disease virus with modifications of the V, F and HN genes.
de Graaf JF; van Nieuwkoop S; Bestebroer T; Groeneveld D; van Eijck CHJ; Fouchier RAM; van den Hoogen BG
PLoS One; 2022; 17(2):e0263707. PubMed ID: 35139115
[TBL] [Abstract][Full Text] [Related]
12. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus.
Puhlmann J; Puehler F; Mumberg D; Boukamp P; Beier R
Oncogene; 2010 Apr; 29(15):2205-16. PubMed ID: 20101224
[TBL] [Abstract][Full Text] [Related]
13. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
14. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
15. Safety and clinical usage of newcastle disease virus in cancer therapy.
Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB
J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816
[TBL] [Abstract][Full Text] [Related]
16. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.
Buijs PR; van Eijck CH; Hofland LJ; Fouchier RA; van den Hoogen BG
Cancer Gene Ther; 2014 Jan; 21(1):24-30. PubMed ID: 24384773
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects.
Schirrmacher V; Griesbach A; Ahlert T
Int J Oncol; 2001 May; 18(5):945-52. PubMed ID: 11295039
[TBL] [Abstract][Full Text] [Related]
19. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.
Apostolidis L; Schirrmacher V; Fournier P
Int J Oncol; 2007 Nov; 31(5):1009-19. PubMed ID: 17912426
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.
Zamarin D; Martínez-Sobrido L; Kelly K; Mansour M; Sheng G; Vigil A; García-Sastre A; Palese P; Fong Y
Mol Ther; 2009 Apr; 17(4):697-706. PubMed ID: 19209145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
